MX2008011520A - Secuencias peptidicas y composiciones. - Google Patents

Secuencias peptidicas y composiciones.

Info

Publication number
MX2008011520A
MX2008011520A MX2008011520A MX2008011520A MX2008011520A MX 2008011520 A MX2008011520 A MX 2008011520A MX 2008011520 A MX2008011520 A MX 2008011520A MX 2008011520 A MX2008011520 A MX 2008011520A MX 2008011520 A MX2008011520 A MX 2008011520A
Authority
MX
Mexico
Prior art keywords
seq
polypeptide
hiv
regulatory
peptides
Prior art date
Application number
MX2008011520A
Other languages
English (en)
Inventor
Gregory Alan Stoloff
Wilson Rome Caparros-Wanderley
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0604920A external-priority patent/GB0604920D0/en
Priority claimed from GB0614260A external-priority patent/GB0614260D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of MX2008011520A publication Critical patent/MX2008011520A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona un polipéptido que no tiene más de 100 aminoácidos, este polipéptido comprende una o más secuencias que tienen al menos 60% de homología con cualquiera de SEQ ID 1-4, o comprende dos o más epítopos que tiene 7 aminoácidos o más, cada epítopo tiene al menos 60% de homología con una subsecuencia de cualquiera de SEQ ID 1-4 que tiene la misma longitud que el epítopo: SEQ ID 1 GDTWAGVEAIIRILQQLLFIHFRIGCQHSR SEQ ID 2 KVGSLQYLALTALITPKKIKPPLPSVKKLTEDRWNKPQKT SEQ ID 3 EPVPLQLPPLERLTLDCSEDCGTSGTQSEQ ID 4 YKGALDLSHFLKEKGGLEGLIYSQKRQDIL DLWVYHTQGYFPD en donde el polipéptido es inmunogénico en un vertebrado que expresa un alelo complejo de histocompatibiliad mayor (MHC) y en donde el polipéptido no es una proteína de virus HIV completa.
MX2008011520A 2006-03-10 2007-03-09 Secuencias peptidicas y composiciones. MX2008011520A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0604920A GB0604920D0 (en) 2006-03-10 2006-03-10 Peptide sequences and compositions
GB0614260A GB0614260D0 (en) 2006-07-18 2006-07-18 Peptide sequences and compositions
PCT/GB2007/000812 WO2007104932A2 (en) 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof

Publications (1)

Publication Number Publication Date
MX2008011520A true MX2008011520A (es) 2009-01-07

Family

ID=38232608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011520A MX2008011520A (es) 2006-03-10 2007-03-09 Secuencias peptidicas y composiciones.

Country Status (21)

Country Link
US (4) US20100055119A1 (es)
EP (2) EP2004676B1 (es)
JP (3) JP2009529570A (es)
KR (1) KR20080106467A (es)
CN (2) CN104558126B (es)
AP (2) AP2015008680A0 (es)
AU (1) AU2007226430B2 (es)
BR (1) BRPI0708708A2 (es)
CA (1) CA2645342A1 (es)
DK (2) DK2004676T3 (es)
EA (1) EA019733B1 (es)
ES (2) ES2573105T3 (es)
HK (1) HK1171027A1 (es)
IL (2) IL193965A0 (es)
MX (1) MX2008011520A (es)
NO (1) NO20083576L (es)
NZ (1) NZ570708A (es)
PL (1) PL2392587T3 (es)
SG (1) SG170092A1 (es)
UA (1) UA97800C2 (es)
WO (1) WO2007104932A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP3077417A1 (en) 2013-12-08 2016-10-12 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
CN116322757A (zh) 2019-11-14 2023-06-23 埃利克斯疗法公司 用于疫苗的剂量方案

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
DE4141970C2 (de) 1991-12-16 1998-02-19 Charite Med Fakultaet Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
ATE177114T1 (de) 1993-10-14 1999-03-15 Seikagaku Kogyo Co Ltd Polypeptide und daraus hergestellte, gegen hiv wirksame substanzen
AU685521B2 (en) 1993-10-19 1998-01-22 Ajinomoto Co., Inc. Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
EP0980388A1 (en) * 1997-05-20 2000-02-23 YISSUM RESEARCH DEVELOPMENT COMPANY of the Hebrew University of Jerusalem Vif-derived hiv protease inhibitors
WO1999013896A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Attenuated vif dna immunization cassettes for genetic vaccines
US6492110B1 (en) 1998-11-02 2002-12-10 Uab Research Foundation Reference clones and sequences for non-subtype B isolates of human immunodeficiency virus type 1
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
EP1155035A2 (de) * 1999-02-19 2001-11-21 Ulrich Schubert Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
CA2397998A1 (en) 2000-01-28 2001-08-02 Statens Serum Institut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
AU2002211490A1 (en) * 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
WO2002069691A2 (en) 2001-03-01 2002-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Immunogenic hiv peptides for use as reagents and vaccines
RU2214274C2 (ru) 2001-08-16 2003-10-20 Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
US6974574B2 (en) * 2001-08-16 2005-12-13 The General Hospital Corporation Methods of inducing an HIV specific response using a Vpr-specific epitope
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
WO2004031345A2 (en) 2002-05-20 2004-04-15 The General Hospital Corporation Cytotoxic t-cell epitopes of hiv-1 virus
EP1578432A4 (en) 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
KR20120086379A (ko) * 2003-09-17 2012-08-02 듀크 유니버시티 컨센서스／원형 면역원
WO2006018289A1 (en) * 2004-08-17 2006-02-23 Institut Gustave Roussy Mutated hiv nef for modulating immunity
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗

Also Published As

Publication number Publication date
ES2616341T3 (es) 2017-06-12
US20170281750A1 (en) 2017-10-05
EA200870342A1 (ru) 2009-02-27
WO2007104932A3 (en) 2007-11-22
HK1171027A1 (en) 2013-03-15
BRPI0708708A2 (pt) 2011-06-07
US8992934B2 (en) 2015-03-31
NO20083576L (no) 2008-12-10
ES2573105T3 (es) 2016-06-06
PL2392587T3 (pl) 2016-08-31
AP3642A (en) 2016-03-16
US20150182618A1 (en) 2015-07-02
CN104558126A (zh) 2015-04-29
EP2004676A2 (en) 2008-12-24
CN102443052B (zh) 2014-12-31
AU2007226430A2 (en) 2008-10-09
NZ570708A (en) 2011-12-22
IL193965A0 (en) 2011-08-01
JP2009529570A (ja) 2009-08-20
EA019733B1 (ru) 2014-05-30
AU2007226430B2 (en) 2013-08-29
IL219544A0 (en) 2012-06-28
JP6422698B2 (ja) 2018-11-14
AP2008004609A0 (en) 2008-10-31
UA97800C2 (uk) 2012-03-26
DK2392587T3 (en) 2016-05-23
EP2004676B1 (en) 2016-11-16
AU2007226430A1 (en) 2007-09-20
EP2392587A1 (en) 2011-12-07
US20130039937A1 (en) 2013-02-14
KR20080106467A (ko) 2008-12-05
US9675686B2 (en) 2017-06-13
SG170092A1 (en) 2011-04-29
JP2013040172A (ja) 2013-02-28
CA2645342A1 (en) 2007-09-20
DK2004676T3 (en) 2017-02-20
EP2392587B1 (en) 2016-05-04
US20100055119A1 (en) 2010-03-04
US10034933B2 (en) 2018-07-31
AP2015008680A0 (en) 2015-08-31
CN102443052A (zh) 2012-05-09
WO2007104932A2 (en) 2007-09-20
CN104558126B (zh) 2020-02-14
JP2015007069A (ja) 2015-01-15

Similar Documents

Publication Publication Date Title
WO2007091030A3 (en) Peptide sequences and compositions
NZ596787A (en) Growth hormone polypeptides and methods of making and using same
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
NZ601345A (en) Combination adjuvant formulation
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.
NZ609216A (en) Anticancer fusion protein
WO2021000969A3 (zh) 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
UA92788C2 (ru) Слитый протеин регуляторных/аксессорных hiv протеинов
EA202190240A1 (ru) Варианты рекомбинантного белка
EP2135876A3 (en) Compositions of polypeptides specific to pathogenic strains and their use as vaccines and in immunotherapy
WO2005068632A8 (ja) ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途
MX2008011520A (es) Secuencias peptidicas y composiciones.
MX2009007261A (es) Vacuna de peptido foxp3.
EP1756143A4 (en) IMMUNOGENEOUS HYBRID POLYPEPTIDES WITH OBESITAS EFFECT AND THESE INGREDIENT IMPREGENT COMPOSITIONS WITH EFFECT AGAINST OBESITAS
TR201902131T4 (tr) Enfeksiyöz bronşit virüsünün (IBV) doku tropizmini uzatan mutant diken proteini.
EP1842911A4 (en) HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS
MX2010005816A (es) Epítopos de péptido de stat3.
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
AU2003239659A8 (en) Peptide epitopes common to antigens of the same multigene family
EP1757687A4 (en) HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR
EP1801211A4 (en) BINDING PEPTIDE HLA MOLECULE, DNA FRAGMENT ENCODING SAME, AND RECOMBINANT VECTOR
WO2010013767A1 (ja) 新規なプロテアーゼおよびその利用
NZ608889A (en) Vaccines based on peptides of the complement protein c5a

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration